Health and Medical News
PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
New FDA Approved Test Detects Thyroid Disease in Minutes
Article Editor: Christopher Simmons
HONEY BROOK, PA - Dec. 28, 2004 /Send2Press Newswire/ -- Thanks to FDA approval of ThyroTest(tm), a new rapid hypothyroid diagnostic screening device from ThyroTec, Inc., detection of a common thyroid disease will now come sooner rather than later for millions of Americans. More Americans suffer from thyroid disease than diabetes and cancer combined.
Currently patients suffering from symptoms of hypothyroidism have to wait days to discover lab results. Because ThyroTest(tm) has also gained CLIA Waiver status; patients can now get test result for hypothyroidism in minutes, right in the doctor's office.
"We are excited about bringing ThyroTest to the marketplace," said Jim Small, president of ThyroTec, a New Jersey based medical products development company. "ThyroTest is the first, and only, product to receive FDA approval and CLIA waiver for identifying above normal levels of thyroid stimulating hormone (TSH) in a rapid format. This simple rapid diagnostic screen test is a qualitative measurement that allows physicians to screen patients for hypothyroidism in ten minutes with a whole blood sample."
Hypothyroidism develops when the thyroid gland does not produce enough thyroid hormone, which regulates body's metabolism. A lack of thyroid hormone affects many body systems.
The incidence of hypothyroidism tends to increase with age, with older people, especially women, at highest risk.
Common symptoms include weight gain, fatigue, mood swings, weakness, dry and coarse skin and hair, hair loss, depression, decreased libido, trouble swallowing, increased cholesterol, heavy or irregular periods or trouble getting pregnant.
An estimated 13 million Americans live undiagnosed and needlessly suffer from hypothyroidism. It is also estimated that three to five percent of the U.S. population has some form of thyroid disease. Approximately one in every eight of American women will develop a thyroid disorder during her lifetime.
ThyroTec has chosen American Health Partners, of Oklahoma City, to develop the ThyroTest(tm) brand identity, final market preparation, selection of national sales partners, training and the management of distribution.
"American Health Partners recognizes the benefit of providing doctors a rapid screen for hypothyroidism. Millions of patients who needlessly suffer from the symptoms of hypothyroidism can be screened in one office visit and further steps for treatment can begin immediately," said Brian Banks, president of American Health Partners.
"American Health Partners brings medical innovations to life through a proprietary market readiness process and proven distribution management network. We look forward to partnering with ThyroTec on this outstanding medical innovation."
ThyroTec, Inc., 1801 Horseshoe Pike, Suite One, Honey Brook, PA 19344. (610) 942-8971. http://www.thyrotest.com
President/CEO, ThyroTec, Inc.,
Source of News:
THIS IS ARCHIVAL CONTENT
Note: for contact information at the organization mentioned in the above PRESS RELEASE, visit the "organization website" (if applicable), or view either version of the original news release using the links below. Send2Press cannot provide contact info.
Business News is powered by
Viewed by the media [MC Error: Error locking file]
Hypothyroid diagnostic screening device, Medical Research, MedTech, Health, Hospitals, thryotec, thyrotec, thyrotech, thyrotest, thryotest, FDA Approval, CLIA Waiver status, hypothyroidism.
USE OF THE ABOVE NEWS ARTICLE
News is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article, or republish the "news release" text version linked to above under "Journalist Tools" without restriction except websites must retain /Send2Press Newswire/ as the source. Sites which offer/sell PR services or newswire services may not reprint our content without express written permission.
FOR INFORMATION ABOUT THE ORGANIZATION(S) MENTIONED IN THE ABOVE NEWS ARTICLE, PLEASE CONTACT THE COMPANY DIRECTLY AND NOT THIS WEBSITE.
DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.